Alivus Life Sciences Signs Shareholders' Agreement to Acquire Stake in IQGEN-X Pharma
Alivus Life Sciences Ltd 路 Others (Uncategorized) 路 11 Nov 2026, 10:22 pm
Alivus Life Sciences Signs Shareholders' Agreement to Acquire Stake in IQGEN-X Pharma Alivus Life Sciences Limited executed a Shareholders' Agreement with IQGEN-X Pharma Private Limited and its continuing existing shareholders (Dr. Mandar Kodgule and Dr. Yogita Kodgule), following a share purchase agreement to acquire a 76% stake in IQGEN-X. Alivus holds an option to purchase the remaining 24% stake after 5 years from transaction closing at a pre-agreed benchmark price. The agreement grants Alivus majority board representation (2 out of 3 directors) without impacting the management or control of the listed entity.
Original exchange filing (PDF)
More announcements from Alivus Life Sciences Ltd
- Enclosed please find herewith update on acquisition. 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nirma Ltd 路 07 Nov 2026
- Please find attached herewith submission with respect to transcript of the earning call. 路 06 Nov 2026
- Please find enclosed herewith intimation for Analyst/Investor meeting. 路 04 Nov 2026
- Please find enclosed herewith intimation for Analyst/Investor Meet. 路 30 Oct 2026
- We hereby confirm that we have uploaded audio recording of the Q2 FY2027 Earnings Call held on October 30, 2026 on the website of the Company. 路 30 Oct 2026
- Please find enclosed herewith intimation with respect to allotment of equity shares under "Employee Stock Option Scheme, 2021" 路 30 Oct 2026
- Please find enclosed herewith Investor Presentation for Q2 FY26-27. 路 30 Oct 2026
